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EVALUATING THE EFFICACY OF A MYCOBACTERIUM BOVIS VACCINE  
 




 Bovine tuberculosis (bTB) is a globally significant zoonotic disease caused 
primarily by Mycobacterium bovis (M. bovis) transmission between wildlife, domestic 
livestock, and humans. Unfortunately in wildlife reservoirs of bTB, disease rates are 
increasing worldwide due to ecological dynamics and challenges in wildlife 
management. Despite effective, long-standing M. bovis eradication programs in the US, 
expanding wildlife reservoir habitat and importation of people, animals, and products 
from the Mexican dairy industry have become sources of zoonotic bTB infection. 
Currently, no tuberculosis vaccine is labeled for use in animals, although a vaccine 
could provide a new tool in preventing bTB in wildlife and domestic livestock. Bacille 
Calmette-Guerin (BCG), a live, attenuated M. bovis strain vaccine used for tuberculosis 
prevention in humans has been variably effective in reducing bTB development in 
studies on various species. We hypothesize that Texas-origin feral swine vaccinated 
orally with either modified-live BCG or inactivated M. bovis vaccine will have fewer, less 
severe lesions than non-vaccinated feral swine after virulent M. bovis challenge. In this 
study we test this hypothesis along with the immunologic response to vaccination and 
infection by measuring antibody levels in vaccinated and unvaccinated swine. Our 
results demonstrate that vaccination with BCG or inactivated strains of M. bovis do not 
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1. Introduction and Literature Review 
 
 
1.1 Mycobacterium bovis – a long history 
 
 Mycobacterium bovis (M. bovis) is a member of the “M. tuberculosis complex” 
group of Mycobacterium bacteria that cause the disease tuberculosis in most 
mammalian species. Mycobacterium bovis is also an etiologic agent of bovine 
tuberculosis (bTB), the most significant zoonotic form of tuberculosis – primarily 
infecting cattle, but transmitted between wildlife, other domestic livestock, and humans 
(1-3). Tuberculosis has plagued the earth since the beginning of recorded human 
history, if not earlier, and is still in the top 10 causes of death in the world as of 2015 (4, 
5). In the early to mid-1900’s the United States (US) and the United Kingdom (UK) 
implemented test and cull eradication campaigns in hopes of ridding their cattle herds of 
bTB. Their efforts eventually reduced the incidence of bTB in both countries to under 
1% for the national cattle population, and to completely disease-free herds and areas of 
the country (2-4). In the UK and US, the disease rates remained very low until the 
1980’s and 90’s when bTB began to spread in greater numbers of animals, herds, and 
across species (6). The Eurasian Badger (Meles meles) in the UK and the white-tailed 
deer (Odocoileus virginianus) in Michigan, USA are well-established wildlife reservoirs 
of bTB that are infected by and transmit to domestic livestock (2). These badger and 
deer populations, serving as maintenance reservoirs for bTB, are an important factor in 
the failure to eradicate bTB in these countries over the past few decades. The UK and 
US examples among multiple countries, highlight the necessity to develop new, 
improved control and prevention efforts in developed areas of the world where wildlife 
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reservoirs are currently involved in reemergence of bTB as a significant source of 
zoonotic disease. If better methods being engineered to reduce bTB prevalence in the 
developed world have practical application, ideally, they could be translated for use in 
the developing world.  
 
1.2 Microbiology of Mycobacterium bovis 
 Mycobacterium species (spp.) are a gram positive, rod-shaped bacterial species 
with a thick, wax and lipid-rich cell membrane which make them essentially impervious 
to traditional Gram staining techniques, so acid fast stains such as Ziehl-Neelson must 
be utilized to visualize them under a light microscope. The outer α-glucan capsular 
layer, along with the waxy and lipid-rich cell wall, can adapt to its host and environment, 
making M. bovis and other mycobacteria particularly resistant to host immune 
destruction, desiccation, acidity/low pH, and antibiotics (7). Standard histopathologic 
fixation and slicing of tissues includes hematoxylin-eosin (H & E) staining of the tissues 
in order to visualize the hallmark of M. bovis and other M. tuberculosis complex species 
infections, the tuberculous granuloma, which will be discussed in following sections. 
Also difficult to harvest in bacterial culture outside of the living host, these slow-growing 
organisms are grown over 8-12 weeks – much longer than other bacteria (8).  
 
1.2.1 Pathophysiology  
 Transmission of pathogenic M. bovis bacteria occurs during direct contact with 
another animal by exposure to bodily fluids and excretions (blood, mucus, urine, milk, 
saliva, feces, etc.) or tissues – e.g. adult animals inhaling aerosolized particles from 
	 3	
each other, neonates drinking infected milk from their mother, or a fetus acquiring the 
infection transplacentally through maternal to fetal blood supply (4). It can also occur 
indirectly by ingestion of contaminated food or milk, skin penetration of the organism via 
wounds, or by coming in contact with fomites and grazing areas on which shedding 
animals have deposited infectious particles (2). Aerosol routes of transmission are 
believed to be the most common between adults of the same species, while ingestion is 
the most common route of transmission to dairy calves and people drinking raw milk, as 
well as for grazing domestic livestock and wildlife (4, 9).  
 Once a host is infected with M. bovis, the bacteria will multiply in macrophages, 
cells that trigger the host’s immune system, to develop characteristic granulomatous 
structures, known as tubercles, at the site of bacterial multiplication. Depending on the 
species, tubercles may consist of various combinations of immune cell layers including 
B cells (bone marrow lymphocytes), T cells (thymic lymphocytes), neutrophils, natural 
killer (NK) cells, Langerhan’s multinucleated giant cells, foam cells, and dendritic cells 
that form around an accumulation of bacteria as they invade host macrophages (4). As 
granulomas mature, they may form caseous, necrotic centers of debris that can further 
develop calcification as the bacteria proliferate and accumulate dead cells and waste 
products in these lesions. Tubercles typically have a thick fibrous tissue encapsulation, 
but less so in some species like deer, in which they grossly appear more like 
abscesses. The tubercles can be large - inches across in diameter - or microscopic. 
This granulomatous process may occur in nearly every host tissue, but are more likely 
in some tissues depending on the host species and disease ecology in a particular area 
of the world.    
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1.2.2 Immunology 
 Much of the immunologic mechanism behind Mycobacterial host immunity has 
not yet been elucidated or is contradictory, and most of our knowledge is from M. 
tuberculosis studies with humans and mice. We do know that innate and acquired 
immune defenses are both involved in fighting against M. bovis infections, and will vary 
to a significant extent in each host, depending on virulence of an M. bovis strain, the 
host species, and individual host genetic variation. The innate immune system is a non-
specific defense unit of the host’s immunity and involves cells such as neutrophils, 
macrophages, T cells, as well as inflammation-mediating chemicals known as cytokines 
(9). Alternatively, the acquired/adaptive immune system learns to develop defenses 
against pathogens after being exposed to them in a vaccine or from an infection, so that 
a more rapid, efficient response to pathogen invasion can be produced upon 
subsequent infection. This adaptive process is led by antigen-presenting cells (APC), T 
cells, B cells, cytokines such as interferon gamma (IFNγ) and interleukins (IL), and 
antibodies among other immune system components (10).  
  Most of the cells and molecules responsible for the formation of tuberculous 
granulomas and the necrosis or caseation at their interior, are the result of innate 
immune responses to M. bovis infection initiated by macrophages that both harbor and 
help destroy this pathogen (11). Delayed-type hypersensitivity reactions and chronic 
inflammation are involved in granuloma development, recruiting immune cells to 
surround infected macrophages and wall off the site with fibrous tissue. Isolating 
infection from the rest of the body and aiding macrophages in destroying M. bovis, 
these granulomas may successfully shield the rest of the immune system from 
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developing a fulminant infection and acquired immunity. Mycobacteria have their own 
protective mechanisms to evade the immune system by manipulating the complement 
system and macrophage dynamics. For example, after phagocytosis of M. bovis by 
macrophages, the bacteria can bind complement receptor 3 and mannose receptors to 
down-regulate the immune response (3). This prevents release of cytotoxic reactive 
oxygen molecules and blocks microbicidal phagosomal activity within macrophages and 
activation of adaptive immunity, leading to intracellular sequestration and avoidance of 
immune system recognition of mycobacteria.  
 If mycobacteria are successful in escaping the innate immune system defenses 
of macrophages and the tuberculous granuloma, the bacteria will multiply and spread to 
other parts of the body, triggering adaptive immune system responses while developing 
fulminant infection. A component of acquired immunity involves the cells mentioned 
above, and relies on the host immune system to recognize and adapt to antigenic 
stimulation, resulting in antibody production. Antigens are chemical structures 
recognized by the immune system as foreign, presented on the surface of APC’s, 
stimulating T cells with many defensive roles and B cells to construct antibodies that 
recognize, bind, and help systematically destroy an organism, in this case 
mycobacteria. The level of antibody formation following mycobacterial infections is 
somewhat dependent on species and immune competency. Because cattle mount a 
significant cell-mediated innate immune response, successfully walling off M. bovis in 
granulomatous foci, antibody production is limited until advanced progression of disease 
(11). In cattle, high antibody levels are believed to be an indication of poor immune 
defense and inability to isolate bacteria in tubercles. Mycobacteria of multiple species 
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and strains have similar antigenic structures, allowing the antibodies of a host to bind a 
variety of mycobacteria, despite only being elicited by a single species. This is one 
mechanism by which vaccines that are produced with M. bovis may be used to defend 
against tuberculosis caused by other mycobacterial species (e.g. M. tuberculosis), but 
often lead to an incomplete protective immunity against infection and can interfere with 
testing to differentiate between infected and vaccinated animals.  
 Cattle or other bovine species are the primary hosts for M. bovis and tend to 
have better species-specific immunity against this bacteria. In comparision to most 
mammals, cattle have more of the unconventional γδ T cells that make them more 
resistant to M bovis infection (11). Cattle and other ruminants also have a higher 
concentration of the cytokines Interleukin-4 (IL-4) and IFN-γ that are released in to the 
bloodstream in response to mycobacterial infections, making these immunologic 
markers for detecting infection or response to vaccination in these species. Vaccines 
designed to prepare the adaptive immune system for M. bovis infection and diagnostic 
tests to detect immunologic response to vaccination have been goals of ongoing 
research with M. bovis.  
 Initial studies in European wild boar allowed for the discovery of genes 
expressing complement component 3 (C3), IFN-γ, IL-4, “Regulated on Activation Normal 
T Expressed and Secreted Cytokine” (RANTES or CCL5), and methylmalonyl CoA 
mutase (MUT) levels are upregulated in vaccinated animals and serve a protective and 
inflammatory function against M. bovis infection (12, 13). The level of C3 and 
MPB83/NADPAD antibodies produced against M. bovis in vaccinated animals was also 
found to correlate with lack of disease severity measured by lesion and culture scoring 
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(13). Ongoing identification of molecular markers (genes, cytokines, proteins, etc) of M. 
bovis infection and vaccine-mediated immunity in feral swine and other species is key to 
further development of diagnostic and preventative technologies for species-specific 
monitoring and control of tuberculosis (14-17).   
 
1.2.3 Clinical manifestation 
 Bovine tuberculosis is typically chronic, and slowly progressive in onset, although 
acute forms can develop. The disease can progress more rapidly in patients with 
immunosuppression, including those with comorbidities, those that are older with 
waning immune system function as well as a longer and higher risk of exposure over 
time, and those with high or chronic levels of stress – which allow for fulminant infection 
or reactivation of a latent infection in an asymptomatic carrier (1). Unfortunately, 
outward appearances make it difficult to identify disease or transmission risk, as not all 
infected hosts are shedding the organism that can transmit disease, and not all 
shedding animals have obvious clinical signs of disease. 
 Clinical signs or symptoms of tuberculosis vary widely, but are often associated 
with lymphadenopathy or pulmonary pathology. The lungs and lymph nodes of the 
head, neck and thorax are the common sites of lesions in hosts infected by inhalation 
(9). Other lymph nodes, organs, gastrointestinal tract, nervous system, genitourinary, 
and hematogenous (bloodstream) sites of infection are less common locations seen 
across the many host species. Lymphadenopathy may lead to fistula tracts draining 
caseous material from superficial lymph nodes to the skin surface. Other signs may 
include ptyalism respiratory distress, dysphagia, airway turbulence, edema and pain. 
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Pneumonia and other respiratory or cardiac dysfunction related to lung damage such as 
pleuritis, cough, hemoptysis, dyspnea, and pericarditis can be seen. Abscesses, organ 
failure, diarrhea or constipation, disorientation and lack of mental appropriateness, and 
severe weight loss are other signs of fulminant M. bovis infection (4). 
 In field studies on wild boar performed in Spain and Italy, M. bovis infection was 
predominantly found in the mandibular, bronchial, mediastinal, and mesenteric lymph 
nodes as well as in the lungs of naturally infected animals hunted in the wild (18, 19). All 
infected animals had mandibular lymph node lesions and one third (30%) of those 
infected only had mandibular lymph node lesions (18). This was in contrast to field 
studies performed on feral pigs in Australia, where a greater percentage (62%) of 
animals had only mandibular lymph node lesions, no pulmonary involvement, and less 
disseminated (systemic) disease manifestation (20). This difference in disease severity 
is important to note due to epidemiologic implications that will be discussed in the 
following section. No draining fistulae at the skin surface originating from the lymph 
nodes were found in pigs; these lesions are suspected to be a source of transmission 
from some other species (2). Recognition of the mandibular lymph nodes as the major 
site of infection, and histologic identification of granulomatous lesions breaking out into 
excretory ducts of the mandibular salivary glands, suggests that oral secretions 
containing M. bovis are one likely source of transmission from pigs. In the Spanish 
study conducted by Martín et. al.,2006, 17% of the wild boar that were euthanized for 
diagnosis of tuberculosis that cultured positive for tuberculosis (22 out of 127) showed 
no macroscopic lesions, and only half of these pigs (11 out of 22) had detectable 
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microscopic lesions, demonstrating the importance of performing tests beyond gross 
post-mortem examination to definitively diagnose tuberculosis (18).   
 
1.3 Epidemiology 
1.3.1 The Global Picture 
 According to the World Health Organization, the annual incidence (new cases) of 
tuberculosis in humans is increasing every year, and in 2015, 10.4 million people were 
newly infected and 1.8 million died from the disease (5). Approximately 35% of people 
with human immunodeficiency virus infection die because they develop tuberculosis, 
emphasizing the danger of contracting this disease in immune-compromised 
populations (1, 5). Zoonotic transmission risk of M. bovis is higher in developing 
countries where livestock and wildlife management, sanitation protocols, and food 
safety regulation are not easily achieved (1, 21). The morbidity and mortality rates 
associated with bTB will vary significantly depending on the species and environment in 
which the disease is found.  Nevertheless, bTB can be a very costly disease for the 
farmers and governments responsible for a region’s cattle industry. Approximately 50 
million cattle were infected with M. bovis globally as of the late 1990’s, with a US $3-4 
billion annual cost to agriculture at that time (2). On a domestic scale, eradication efforts 
put forward to successfully create a bTB-free designation in the state of Minnesota 
alone after an outbreak in 2005 cost federal and state agricultural organizations over US 




1.3.2 Human-Wildlife-Livestock Interface 
 In some developed countries like the US, New Zealand, Spain, Ireland, and the 
UK, there have been outbreaks and increasing incidence of bTB despite long-standing 
test and cull programs for domestic cattle (2, 3, 22, 23). In regions with established 
“maintenance” wildlife reservoirs (animals that readily transmit the pathogen to and from 
other susceptible host species) of bTB such as white-tailed deer (Odocoileus 
virginianus) in Michigan, European badger (Meles meles) in Ireland and the UK, and 
wild boar (Sus scrofa) in Europe, the incidence of tuberculosis is increasing due to 
these wildlife reservoir populations outgrowing their habitats and due to the complexities 
in their management (24-26). New Zealand is one country with an established wildlife 
reservoir of bTB, the brushtail possum (Trichosurus vulpecula), that has successfully 
reduced disease incidence by intensive population control of this invasive non-native 
species, as it simultaneously promotes conservation of forest ecosystems (27). The 
likelihood of spillover to wildlife and spillback to domestic livestock can be encouraged 
by a number of factors including transport of wildlife to new areas, feed supplementation 
of wildlife that crowds animals into one area, protected wildlife species legislation 
leading to uncontrolled population growth, and failed attempts to keep wildlife off of land 
that domestic livestock inhabit (2).  
 Typically, zoonotic and reverse-zoonotic spread of bTB is via direct contact with 
cattle or consumption of contaminated raw dairy or meat products, but can also be the 
result of direct contact with captive wildlife (in zoos, rehabilitation centers, sanctuaries) 
and infected game carcasses (4, 28, 29). Transmission between animals and people 
also depends on disease ecology – population density, severity and length of disease 
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as it affects shedding capacity, geographical influences on the range and overlap of 
multiple-species habitats, and climate in regards to survival of host and pathogen in the 
environment (2, 18). M. bovis is particularly good at surviving in cool, moist climates 
with limited sunlight, and was found to persist up to 88 days in soil, 58 days in water and 
hay, and 43 days on corn in a study done in Michigan to investigate the risk of indirect 
transmission between cattle and white-tailed deer (30). Studies in Spain on wild boar 
populations have identified artificial water and feeding sites, scarce water sources in 
drought season, containment in fenced hunting and wildlife refuges, and translocations 
as factors encouraging aggregation and close interaction that increases M. bovis 
transmission risk within and across species (26).  
 “Dead-end” hosts, as opposed to maintenance reservoir hosts, may be 
designated in species that tend to be infected, but typically develop mild to non-existent 
clinical signs or pathologic lesions, so that transmission does not readily occur from 
them to other hosts. Determining whether a particular species is considered a 
maintenance reservoir versus dead-end host will vary based on the disease ecology, 
socioeconomic environment, and epidemiology – e.g. disease prevalence and incidence 
– in a particular area of the world (2). For example, feral pigs in the previously 
mentioned Australian study were considered a dead-end host of bTB, because the vast 
majority of cases had lesions limited to a localized area of the body – the mandibular 
lymph nodes (20).  In studies with European wild boars, disease manifestation was 
disseminated throughout the body, more severely affecting this species, so they are 
considered a maintenance reservoir in this location (18). DNA sequencing, restriction 
fragment length polymorphism (RFLP) analysis, and spoligotyping (DNA fingerprinting 
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techniques) have confirmed that the genotypes of M. bovis strains in European wild 
boar and North American white-tailed deer matched those from cattle within their 
respective regions. These molecular epidemiologic tools by which wildlife hosts of bTB 
can be identified as maintenance reservoirs are used to trace and implicate 
transmission events (21, 31, 32).  
 Despite previously effective M. bovis eradication strategies in domestic cattle 
herds and federally regulated pasteurization of dairy products in the US, bTB 
persistence in wildlife reservoirs and constant importation of cattle and dairy products 
from Mexico are expanding sources of zoonotic bTB infection in the US (22, 29, 33-35). 
Along with the northern US (Michigan) having to improve bTB control efforts with the 
region’s white-tailed deer bTB reservoir, there has also been a notable increase in bTB 
incidence in Southern California. The incidence of bTB in cattle has persisted in both 
Michigan and California, not dropping low enough to designate a tuberculosis-free 
status (36).  In pockets of the US, where the increasingly popular practice of consuming 
unpasteurized, fresh cow milk and cheese is occurring, people are contracting bTB from 
contaminated raw dairy products. A global study on zoonotic tuberculosis found 
particularly high percentages of bTB incidence in Latin American communities of San 
Diego, New York, and from Mexico compared to the proportion of human tuberculosis 
due to M. bovis around the world (4). In San Diego county, California from 1994-2005, 
the incidence of M. tuberculosis was falling while the incidence of M. bovis was 
increasing, with 45% of childhood and 6% of adult tuberculosis cases caused by M. 
bovis (37). Also concerning is that the likelihood of death from zoonotic M. bovis in this 
setting is twice the rate of death caused by M. tuberculosis, and 2.6-8.3 times higher in 
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HIV patients in various parts of the US (4). The exact cause of this higher mortality rate 
is not fully understood, but it may be attributed to limited health care access for this 
ethnic population, inappropriate treatment with M. tuberculosis targeted drugs and 
timeframes, and perhaps the difficulty of treating extra-pulmonary forms of tuberculosis 
due to ingestion rather than inhalation of M. bovis (29).  
 
1.3.3 Wild and Feral Swine 
 More than 15 countries have discovered bTB in wild or feral swine species (22, 
29, 34, 38-40). A few broad surveillance studies on feral swine in the Southern Texas 
border region (41), other US mainland states, and Hawaii (35, 42, 43) found a lack of M. 
bovis, despite some of these animals’ proximity to known outbreaks of bTB in cattle and 
cervid populations. It is important to determine whether feral swine in the US are 
currently negative for M bovis, as they pose a potential risk for becoming a reservoir, 
and epidemiologic surveillance should be ongoing if outbreaks continue to occur in 
cattle and human populations. The map of the US mainland and Hawai’i (Figure 1) 
illustrates the range of expansion in the feral swine population as it has grown from 
1982 to 2015 (44). 
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Figure 1: USDA map of range of expansion in the feral swine population from 1982 to 2010 (44). 
 
 
As these swine populations expand across states and into northern Mexico where bTB 
infection exists in cattle, white-tailed deer, and humans, the risk of feral swine becoming 
maintenance reservoirs is increasing (35, 36, 45). Ongoing epidemiologic and ecologic 
surveillance of infectious disease, behavior, migration, and interspecies interactions in 
feral swine in these areas of North America will be essential (35).  Updated studies 
should be performed on Molokai island where bTB last had a significant prevalence of 
approximately 20% (38), but was largely mitigated by culling infected cattle, swine, and 
deer. A more recent survey of feral swine found 5 out of 482 animals testing positive for 
M. bovis (1%) on Molokai, with transmission being prevented by keeping cattle away 
from areas inhabited by feral swine (35). Because swine are culturally protected and 
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prized as hunting bounty on Molokai, population growth as well as exposure of people 
to infected game carcasses could pose a transmission risk. Feral swine population 
dynamics, intensive livestock grazing, the practice of wild game feeding, baiting, and 
hunting in broadening ranges of the US form a combined threat of multi-species M. 
bovis transmission as it has been demonstrated in European wild boar and North 
American white-tailed deer (22, 46).  
 
1.4 Diagnosis, Treatment, Prevention 
1.4.1 Diagnosis  
 Culture is the gold standard for diagnosis of M. bovis, but the most practical 
methods for testing large populations of people and animals are less time consuming 
and more cost effective (28). Mycobacterium bovis is harvested using one of the 
following culture media: modified Löwenstein-Jensen (with pyruvate and without 
glycerol), Stonebrink’s, tuberculosis bovine blood agar, or modified Middlebrook 7H11 
agar. Culture samples are typically collected from post-mortem tissues in animals, but is 
more often an ante-mortem diagnostic tool when used in humans.  
 Intradermal testing is the most readily performed test to diagnose tuberculosis in 
developed countries. It can be done using tuberculin purified protein derivative (PPD), 
an M. bovis antigen that is injected into the dermal layer of skin and examined after 72 
hours for a delayed type hypersensitivity (DTH) reaction caused by recognition of the 
acquired cellular immune system to the antigen after pre-exposure or infection with 
Mycobacterium spp. (skin swelling and induration/reddening at site of injection). This 
type of skin test is used routinely in dairy cattle herds and in the human population to 
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detect infection or exposure to M. bovis or M. tuberculosis with a sensitivity of about 70-
75% (11).  It is used in countries that do not have endemic tuberculosis, because a 
positive result would occur in too many patients being tested in parts of the world where 
vaccination or disease are common, as it does not differentiate vaccination from 
exposure/infection. There can also be a cross-reaction between different mycobacterial 
species, complicating this test result, so confirmatory testing may need to be performed. 
For example, human patients are most often infected with M. tuberculosis and dairy 
cattle may be infected with M. avium paratuberculosis (MAP), although they both have 
the potential to react to the M. bovis antigen whether they are actually infected with M. 
bovis or not (4). A comparative cervical intradermal tuberculin skin test with antigen 
from MAP is one test that can differentiate an M bovis infection from a non-specific DTH 
reaction to mycobacteria in animals. Additionally, a test that must be read 72 hours later 
is not a feasible way to monitor wildlife that are difficult to capture and should not be 
subjected to repeated stressful handling in such a short time (28). Other confirmatory 
tests recognizing cell-mediated immune responses to disease are lymphocyte 
proliferation and IFN-γ whole blood assays (4). The cytokine IFN-γ, as discussed in the 
immunology section, is upregulated during mycobacterial infection, so levels can be 
monitored in some ruminant, human, and non-human primate species that the test has 
been validated for (11, 28). The IFN-γ release and Interleukin-17A assays, as well as a 
skin test using M. tuberculosis complex rather than M. bovis PPD antigens are some 
useful diagnostic tests to differentiate infected from vaccinated animals (DIVA tests), but 
more of these types of DIVA tests are needed (47-52). 
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 Enzyme linked immunosorbant assays (ELISA) and similar tests have been 
developed to detect specific anti-M. bovis antibody detection in serum. Serologic tests 
tend to be logistically better for application in the field, as the antibodies are stable 
during sample transport, and the costs are relatively low compared to other tests with 
similarly high specificity (28).  As discussed in the above immunology section, animals 
may have varying levels of antibody response to bTB and M. bovis vaccination based 
on species, age, and stage of disease. Serological assays such as the lateral-flow 
immunochromatographic test, the species-specific multi-antigen print immunoassay 
(MAPIA), and the dual-path platform assay (DPP) have been developed to detect a 
variety of antibodies. Antibody detection is especially ideal for wildlife M. bovis testing, 
as some of them are rapid, “animal-side” tests or can be run on large numbers of 
animals at once, but are currently only commercially available for use in elephants, 
some deer and camelid species, badgers, and primates (28).  In one study with wild 
boar, the DPP assay had the highest specificity (89.6%) and the bovine purified protein 
derivative (bPPD) ELISA was the test with the highest sensitivity (100%) depending on 
the cutoff value used (28). A PPD based ELISA has the potential for cross-reactivity, as 
it does in the tuberculin skin test form, so this can lower specificity due to the presence 
of environmental mycobacteria in some animals. Additionally, testing an animal once for 
antibody levels has limited utility for interpreting disease prevalence on its own, as it can 
indicate previous exposure as well as concurrent infection.  
 Polymerase chain reaction (PCR) or other genotyping technologies for DNA 
fingerprinting of mycobacterial strains (Restriction Fragment Length Polymorphism or 
spoligotyping) are more precise although lengthy techniques, as some are used to 
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identify Mycobacterium spp. after culture isolation or post-mortem examination has 
been performed (31, 32, 53). These methods can be used to test populations of 
subjects in any epidemiological climate, although with more significant costs associated 
with laboratory equipment and supplies.  
 Ultimately, the goal is to develop a diagnostic that combines a DIVA test with 
high specificity for M. bovis, availability at a reasonable cost, high efficiency to test with 
one sampling event, compatibility with field use, and production of timely results when 
simultaneously testing large numbers of multiple species (28). In most developing 
countries, advanced confirmatory testing methods are not available, so differentiation 
between infections with M. bovis and other Mycobacteria spp. are not made (4).  This 
limits making the distinction between zoonotic and human-to-human transmitted 
tuberculosis, therefore limiting the ability to adequately track, monitor, prevent and treat 
infections as well. 
 
1.4.2 Treatment 
 The conventional treatment for tuberculosis is a 6-month course of isoniazid, 
rifampin, ethambutol, and pyrazinamide antibiotics in people. Although there is an 
effective medical cure for human patients with uncomplicated M. tuberculosis infections, 
extrapulmonary tuberculosis, especially caused by M. bovis, is notoriously difficult to 
treat (29).  Mycobacterium bovis has an innate resistance to pyrazinamide antibiotics, 
and an extended course of antibiotics should be used to effectively treat M. bovis 
infections. Unfortunately, most physicians around the world do not differentiate between 
M. tuberculosis and M. bovis before initiating treatment in people, and research has 
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shown that M. bovis causes a higher rate of mortality than M. tuberculosis (29). Multi-
drug resistant and rifampin resistant strains of tuberculosis also complicate therapy, and 
were found in 580,000 combined new cases in 2015 (4). Treating animals with multi-
drug therapy is not typically practiced, as it does not inhibit spread of infection, complete 
cure is difficult to achieve, it tends to be cost prohibitive, and it may not be allowed in 
food-producing species.  
 
1.4.3 Prevention and Control 
 Since the early 1900’s, most of the developed world has kept the incidence of 
bTB in domestic livestock extremely low with monitoring and control programs (33, 54, 
55). Government and industry organizations in the US have carried out effective bTB 
eradication efforts in domestic livestock using tuberculin skin testing and removal 
protocols, as well as carcass inspection and condemnation at slaughter (56). Complete 
eradication will not be possible if wildlife reservoirs continue to maintain the disease due 
to domestic livestock transmission (spillover) and wildlife transmission back to the 
domestic species (spillback) (2). While culling wildlife reservoirs may appear to be a 
feasible solution to the threat of bTB at the wildlife-livestock-human interface, it may go 
against protections for certain wildlife species – based on whether the species is native 
or non-native, invasive or not, socially valued, etc. – and may not be effective given the 
particular environment in which these control efforts are made (3, 6, 29, 57). As 
described above, multiple approaches to enhanced disease surveillance, wildlife 
management, and control in all species involved have been explored over the last few 
decades (26, 35, 42, 58-61), and goals have been to minimize disruption of natural 
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habitats, avoid stressful handling of animals, and optimize efficacy of biotechnology in a 
restrictive field setting. No tuberculosis vaccine is available for widespread distribution in 
animals, but an effective and practical, ideally species-specific, vaccine would provide a 
key addition to preventing the spread of disease and reducing financial burden of bTB in 
wildlife, humans, and domestic livestock (2, 55, 62).  
 
1.5 Mycobacterium bovis Vaccination 
1.5.1 Bacille Calmette-Guérin (BCG) Modified-live M. bovis Vaccine 
 BCG is a live, attenuated strain of M. bovis that has been used to vaccinate 
people against tuberculosis worldwide since the 1920’s. It was developed by the two 
French scientists it was named after, and is used regularly to vaccinate babies and 
young children in populations with endemic tuberculosis. Although BCG has been the 
standard for tuberculosis vaccination for nearly a century, and is the only vaccine 
licensed for use in people, there are notable disadvantages to its use in human patients. 
BCG only induces the most consistent and effective protection in immunologically naïve 
human vaccinates (3). Efficacy is measured by a more consistent reduction in the 
severity of clinical disease, thereby reducing the shedding and transmission of virulent 
tuberculosis-causing organisms into the environment as well (3, 55). Ongoing research 
has determined factors interfering with vaccine success in people, most notably in 
developing countries, such as exposure to environmental mycobacteria, chronic 
parasitic infestation, co-morbidities with immunosuppressing infections (e.g. HIV), 
malnutrition, and dosage of tuberculosis pathogen exposure (55). These factors 
certainly translate to vaccination failure in animals, as BCG has shown variable efficacy 
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in animal studies as well – geographic location, breed or species of animal, age of the 
animal at vaccination, and the disease ecology can all play a role (3, 63, 64). Although 
veterinary research trials being conducted around the world have shown BCG to impart 
some protection against experimental or natural challenge with M. bovis in animal 
reservoirs such as badgers, white-tailed deer, possums, cattle, buffalo, and wild boar, it 
is not always reliable at preventing significant disease, and limited testing has been 
performed in the field (11, 12, 24, 64-72).  Additional disadvantages to using the vaccine 
in animals is that, as a modified-live vaccine, BCG is unstable for extreme temperature 
fluctuations in an outdoor setting and poses an exposure hazard to people and non-
target species when administered in non-endemic areas (73). BCG must be used 
cautiously, if at all, in locations where exposure to the vaccine can cause a disease-
positive test result – i.e. countries like the US where skin testing is the primary method 
for diagnosis in people and cattle (3). Although feral swine that have been vaccinated 
with BCG did not carry traces of the M. bovis vaccine strain in their tissues on necropsy, 
and did not cause unvaccinated animals inhabiting the same environment to react to TB 
skin testing, another study on white-tailed deer did demonstrate persistence of BCG in 
tissues, but not in co-habiting animals (39, 54, 65, 95). This would theoretically allow us 
to administer BCG safely in a controlled setting, but may be impractical for dispersal to 
large populations of wildlife that have the potential to be consumed by people. If the 
vaccine were released into the environment itself from spillage or in a dispensed form, it 
could cause unwanted exposure and positive tuberculin skin tests in both domestic 
cattle and people (68).  
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This is one reason why ongoing improvements to diagnostic tests that differentiate 
infection from vaccination (DIVA tests) will also make development of a universally 
adaptable vaccine strategy easier as well (3, 54, 55, 62, 74).  
 
1.5.2 Alternatives to BCG vaccines 
 Development of a more reliably efficacious, practical, stable, and less 
biohazardous vaccine than BCG is needed for use in vaccinating wildlife and domestic 
animals (3, 4, 14, 23, 24, 26). In the last few decades, vaccine trials in animals have 
demonstrated improved efficacy of vaccination when using BCG in combination with a 
booster of DNA, protein, or viral vector subunit vaccine (11, 75-77), but they are not 
efficacious when used on their own. Oral baits for delivery of vaccines have been 
developed for non-invasive, mass distribution to wildlife populations, and some 
successful palatability and efficacy results in feral swine/wild boar studies in Spain and 
the US have been demonstrated (39, 59, 73, 78-81). Heat-inactivated vaccines have 
been tested as well, as they are more stable under temperature fluctuations than 
attenuated vaccines, and do not pose a risk of tuberculin skin or IFN-γ release assay 
testing reactions in domestic cattle that ingest them in oral baits (13, 73, 82). 
 The first research on M. bovis vaccination in wild boar was performed in Spain, 
showing that oral bait administration of either BCG or an inactivated (heat killed) M. 
bovis vaccine resulted in significant decreases in bTB disease severity after 
experimental infection when compared to unvaccinated control groups (12, 13, 73). This 
was the first attempt to vaccinate against tuberculosis in any wildlife species using a 
temperature-stable, killed-inactivated Mycobacterium spp. vaccine (73).  
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The threat of bovine tuberculosis (bTB) transmission in the US is rising as a 
result of greater interaction between wildlife, livestock and humans, lack of consistently 
safe and effective control measures in wildlife, importation of cattle and dairy products 
from Mexico, and wildlife population expansion (36, 55). Eradication efforts in developed 
countries, including the US, helped reduce the prevalence of M. bovis in domestic 
livestock to very low levels, but these populations are continually being threatened with 
outbreaks as the wildlife reservoirs of bTB are maintaining the disease with spillover 
and spillback phenomena (2, 83, 84). As wild boar serve as established wildlife 
reservoirs of bTB in several European countries, feral swine have the potential to 
become reservoirs in North America under similar pressures from disease ecology, and 
development of a reliable vaccination scheme would help mitigate an outbreak involving 
this species (22, 35).  
 While the modified-live M. bovis bacille Calmette-Guerin (BCG) is the only 
vaccine labeled for use in humans, it has not been able to consistently stop 
transmission of disease in enough people on its own to control tuberculosis in most of 
the world. Likewise, it confers variable protection against M. bovis infection in human 
and animal species (3, 55, 64). An ideal bTB vaccine template for use in wildlife species 
would be stable in the field, minimize stressful animal handling, and be safe for any 
person or animal exposed to it during distribution. Testing of inactivated M. bovis strains 
and oral bait delivery systems have had some promising results in initial wild boar 
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studies in Spain (12, 73). Demonstrating the palatability of oral baits, and efficacy of 
BCG and inactivated M. bovis vaccines, Spanish wild boar trials have shown less bTB 
disease severity in vaccinates when compared to unvaccinated controls (12, 59, 78, 
79). Wild boar vaccinated with an initial and booster BCG vaccine and then challenged 
with virulent M. bovis revealed a 75.8% and 66.9% reduction in lesion and culture 
scores, respectively, when compared to control animals (24). Another Spanish study 
using parenteral and orally-administered inactivated M. bovis, as well as oral modified-
live BCG vaccines, demonstrated a reduction in average lesion scores by 43.3%, 43.3% 
and 52.2%, and a reduction in average thoracic culture scores by 66.7%, 33.3%, and 
66.7%, respectively, in comparison to non-vaccinated controls (73).  
 In this study, we compared the efficacies of orally administered heat-inactivated 
M. bovis strains obtained from Spain and Michigan, USA to each other and to modified-
live BCG vaccines administered before experimental infection with virulent M. bovis in 
Texas-origin feral swine. Our study was in collaboration with researchers from previous 
Spanish trials at the Instituto de Investigación en Recursos Cinegéticos (IREC) 
Universidad de Castilla-La Mancha in Ciudad Real, Spain and Neiker Tecnalia in 
Bilbao, Spain. We were not able to demonstrate that any of the three M. bovis vaccines 
were protective in the face of pathogenic M. bovis challenge. This research also showed 
no significant difference between IgG antibody levels against bPPD antigen, 
macroscopic or microscopic (histopathology) lesion scores, or culture between 




2.2 Materials and Methods 
2.2.1 Subjects 
 
 Twenty nine piglets were produced from a tuberculosis-free captive population of 
Texas-origin feral swine housed at the United States Department of Agriculture 
(USDA)/Colorado State University (CSU) Wildlife Research Facility (WRF) in Fort 
Collins, Colorado, USA. The piglets were born in early spring 2015 and were housed 
with access to fresh water and pelleted pig feed in outdoor pens at the WRF and later 
indoors at the Animal Disease Laboratory (ADL), a biosecurity level 3 facility on the 
CSU Foothills campus. All experiments were approved by the CSU Institutional Animal 
Care and Use Committee (IACUC) under protocol #14-5367A.  
 
2.2.2 Inactivated Michigan/Spanish strain M. bovis vaccine preparation  
 The Spanish and Michigan M. bovis strain killed-inactivated vaccines were 
prepared by Neiker Tecnalia in Bilbao, Spain as previously described (73). The Spanish 
M. bovis strain (#1403, Neiker) was obtained from a naturally infected wild boar in 
Spain. The Michigan M. bovis strain (14-03411) was obtained from a cow in a bTB 
outbreak in 2014 in Michigan, USA. The isolates were grown in Middlebrook 7H9 
enriched broth containing Oleic acid-Albumin-Dextrose-Catalase (OADC Enrichment; 
Difco) for 2-3 weeks. After harvesting via centrifugation at 2500 x g for 20 minutes, cells 
were washed twice in phosphate buffered saline (PBS). Bacterial pellets were 
resuspended in PBS and a fine needle syringe was used for declumping. The optical 
density of suspension turbidity was adjusted to 5 McFarland units. The antigenic dose 
was measured by determining the colony forming units (CFU) per unit volume in the 
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production batch, with ten-fold serial dilutions prepared and plated onto agar-solidified 
7H9 with OADC in quadruplicate. The inocula were inactivated in an airtight bottle in a 
water bath at 83-85◦C for 45 minutes. Four 0.5mL samples of the inactivated batch were 
inoculated in BACTEC Mycobacterial Growth Indicator tubes (Becton Dickinson) and on 
separate OADC agar solidified 7H9 plates (100µL each) and monitored for 60 days to 
confirm negative growth and viability of the bacterial isolates. The oral vaccine was 
shipped from the manufacturer at a concentration of 1x106 CFU killed M. bovis per 
0.2mL and was diluted at 3mL per 12mL of 7H9 to provide 1x106 CFU killed M. bovis in 
1mL of diluted fluid volume.  
 
2.2.3 Modified-live BCG strain M. bovis vaccine preparation 
Frozen BCG stock was received courtesy of T. Thacker at the USDA/ARS National 
Animal Disease Center, Ames, Iowa, USA. The BCG stock was frozen at a 
concentration of 7.9 x 109 cfu/mL and thawed and diluted to 2.6 x 106 cfu/mL in 
phosphate buffered saline (PBS) as a working solution. 
 
2.2.4 Vaccination 
 Swine subjects were randomly divided into four treatment groups: 1) eight 
animals were orally administered 1mL of 1x106 CFU heat-killed M. bovis Michigan strain 
[Michigan group], 2) seven animals were orally administered 1mL of 1x106 CFU heat-
killed M. bovis Spanish strain [Spanish group], 3) seven animals were orally 
administered 1mL of 1x106 CFU modified-live BCG [BCG group], and 4) seven animals  
were orally administered 1mL water as controls [control group]. All four groups were 
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administered vaccine or water via syringe attached to a urinary catheter aimed at the 
oropharyngeal mucosa, introduced into the mouth through an oral speculum. Animals 
were manually restrained in a Panepinto pig sling (Figure 2) for these procedures (85). 
The two groups receiving killed M. bovis (Spanish or Michigan) were vaccinated in 
August 2015 (prime/initial) and September 2015 (1 month booster). The two groups 
receiving BCG and placebo vaccine were administered only one dose in August 2015. 
Each group was housed completely isolated from one another throughout the entire 
experiment.	
	
Figure 2: Pig subject restrained in the Panepinto sling 
For vaccination via oral speculum and catheter. 
	
	
2.2.5 Challenge with Pathogenic Mycobacterium bovis 
 Two months after initial vaccination (October 2015), all animals were 
anesthetized and transported in a standard stock trailer a distance of 0.5 miles from the 
WRF to the ADL. Either a combination of intramuscular butorphanol-medetomidine-
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midazolam (0.3 mg/kg; 0.06 mg/kg; 0.3 mg/kg respectively) or telazol-medetomidine (3 
mg/kg; 0.05 mg/kg respectively) was used for anesthesia in each subject administered. 
 Stocks of Michigan deer M. bovis strain TB14-03411 were received from the 
National Veterinary Services Laboratory and inoculated onto agar plates.  Those 
cultures were incubated at 37C for 17 days, at which time nice lawns had developed.  
Plates were flooded with phosphate buffered saline (PBS) and bacteria were harvested 
with a swab.  Those suspensions were sonified to break up clumps and counted using a 
Petroff-Hausser chamber.  The resulting titer was 2.3 x 109 bacteria/5 ml, and that 
suspension was diluted 1:2300 in PBS to yield an inoculum with a concentration of 
106/5 ml. 
 After an acclimation period of 42 days in the ADL, 4 months post-initial 
vaccination, all animals were anesthetized with the telazol-medetomidine as previously 
described (86) via darts (Pneudart Inc., Williamsport, PA, USA) projected from a CO2-
powered dart pistol (DanWild LLC, Austin, TX, USA). The subjects were then 
challenged with 1x106 M. bovis bacteria as described above, following a previously 
developed protocol and verified adequate dose for experimental infection via 
oropharyngeal route (12). 
 
2.2.6 Enzyme Linked Immunosorbant Assay (ELISA) Serology  
 Blood samples of approximately 5mL were collected by phlebotomy using a 1.5 
inch, 18 gauge needle and 10mL syringe from the anterior vena cava of all swine either 
while in Panepinto sling restraint at the WRF or under anesthesia in the ADL. Samples 
were obtained from pigs pre-vaccination (time 1), four weeks post-vaccination with killed 
	 29	
vaccines (time 2), sixteen weeks post-vaccination/time of pathogenic M. bovis challenge 
(time 3), five weeks post-challenge (time 4), and at time of euthanasia and 
necropsy/fifteen weeks post-challenge (time 5). The serum was analyzed for 
immunoglobulin G (IgG) antibodies against bovine purified protein derivative (bPPD) M. 
bovis antigen using ELISA. Serum antibody levels were determined using a bovine 
purified protein derivative (bPPD) ELISA protocol developed by researchers at the 
Instituto de Investigación en Recursos Cinegéticos (Institute for Game and Wildlife 
Research - IREC) Sanidad y Biotecnoligía (Health and Biotechnology - SaBio) group at 
the Universidad de Castilla-La Mancha (University of Castilla-La Mancha) in Ciudad 
Real, Spain. The bPPD ELISA was designed to detect protoplasmic antigen antibodies 
associated with M. bovis infection. The protocol was optimized for performance at the 
CSU Animal Population Health Institute Laboratory using an ELx 405 autoplate washer 
(Bio-Tek Instruments, Inc.) as described previously (87) with some alterations (see 
Figure 4 for schematic of technique): after coating the plates with 50 µL of cervical 
bPPD tuberculin (lot # 31-CER 1401, June 2016, NVL – Ames, IA) at a concentration of 
5 µL PPD/mL of bicarbonate buffer (Pierce Biotechnology, Inc., Rockford, IL) for 48 
hours at 4◦C, the wells were washed 6 times with phosphate buffered saline (PBS) 
(AMRESCO MidSci, Solon, Ohio) solution containing 0.05% Tween 20 – (BioRad Labs, 
Hercules, California) (PBST) and blocked for 1 hour at room temperature (RT) by 
adding 100 µl of 5% skim milk (BioRad Labs) in PBST to each well. After aspirating the 
blocking solutions out of each well, a 1:40 dilution of sera in PBS were added to plates 
(50 µl/well) diluted down the plate into 1:80, 1:160, 1:320, 1:640, 1:1280, and 1:2560 
concentrations.  For the positive control, dilutions of 1:200, 1:400, 1:800, 1:1600, 
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1:3200, and 1:6400 were tested, and for the negative control a 1:40 dilution was used.  
Plates were incubated for 1 hour at RT. Samples were tested in duplicate on each plate, 
while positive and negative controls were tested in singles on every testing plate. 
Positive and negative control serum was obtained from confirmed M. bovis culture-
positive and culture-negative wild boar from Spain (kindly provided by C. Gortazar and 
T. Anderson). After washing 6 times with PBST, recombinant protein G-peroxidase 
conjugate (1mg/mL, catalog number 31449 ThermoFisher Scientific, Waltham, MA 
USA) milk blocking solution was added to each well at a concentration of 0.5 µL protein 
G/mL as a conjugate (50 µL per well) and incubated at RT for 80 minutes in the dark 
before washing again 6 times with PBST. Color production was induced using 50 
µL/well of 3, 3’, 5, 5’-tetramethylbenzidine (TMB) (Promega Corp., Madison, WI, USA) 
for 20 minutes in darkness. The reaction was stopped with 50 µL/well of 3N sulfuric 
acid, and optical density (OD) was measured in a Spectra MAX plus 384 microplate 
spectrophotometer (Molecular Devices Corp., Sunnyvale, CA, USA) at 450nm 
absorbance. Serum sample results were represented by the average OD (at a 1:40 
dilution) for each sample and compared at each time frame (Time 1-Time 5). Antibody 
levels were also represented using an ELISA percentage (E%) and calculated as 
previously described (13, 60, 73, 87) using the formula:  
 Sample E = (mean sample OD/2 X mean negative control OD) X 100 
If a sample E% was greater than 1, it was considered positive. 	
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Figure 3: Enzyme linked immunosorbant assay (ELISA) diagram illustrating the titration technique used 




2.2.7 Euthanasia and Necropsy with Lesion Scoring 
 In March 2016, 15 weeks post-challenge with pathogenic M. bovis, all groups 
were anesthetized with the telazol-medetomidine protocol described above, humanely 
euthanized via captive bolt gun, and necropsied at the ADL immediately after time of 
death. Prior to euthanasia, none of the animals in any group displayed overt signs of 
clinical disease. Assessment of gross pathology was noted on post mortem 
examination. Tissues targeted for examination included: lung lobes (diaphragmatic, 
cranial, cardiac, accessory), visceral organs (liver, spleen, kidney, ileocecal intestinal 
junction), and lymph nodes (mandibular, parotid, retropharyngeal, mediastinal, 
tracheobronchial, bronchial, superficial cervical, mesenteric, ileocecal, tonsils, and 
hepatic) – see score worksheet in Appendix 1. Macroscopic lesion scoring was 
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performed according to a previously published rubric (73) and was based on size and 
number of lesions. Lung lobe scoring ranged from 0-5: 0 = no visible lesion, 1 = few 
<1cm caseous foci (“A” lesions) scattered throughout lobe, 2 = numerous or clustered 
“A” lesions with some coalescence of foci, 3 = “A” lesions densely clustered throughout 
the lobe, 4 = at least one lesion >1cm (“B” lesion), 5 = two or more “B” lesions.  Visceral 
organ scoring ranged from 0-2: 0 = no visible lesion, 1 = 1-2mm foci scattered 
throughout the organ, 2 = 5-10mm diameter clusters of 1-2mm foci or a single “B” 
lesion. Lymph node scoring ranged from 0-4: 0 = no visible lesion, 1 = 1-2 small “A” 
lesions, 2 = several “A” lesions, 3 = several foci with at least one “B” lesion, 4 = diffusely 
distributed lesions. Calcification and necrosis were also noted for each target tissue 
examined as an indication of more advanced lesion pathology.  
 
2.2.8 Histopathology and Bacterial Culture 
 Histopathologic examination was performed on all target lymph nodes and 
tissues listed above and in Appendix 1 by fixing cut tissues in 10% neutral-buffered 
formaldehyde, embedding them in paraffin, and slicing them at approximately 4-5µm 
thickness before staining with hematoxylin-eosin stain. Some slides were also selected 
to be fixed with acid fast stain as well to help detect the presence of acid-fast bacilli. 
Slide fixation was performed at USDA, Animal and Plant Health Inspection Service 
(APHIS), National Veterinary Services Laboratory (NVSL) in Ames, Iowa. Slides were 
read on a standard light microscope to detect the presence of microscopic lesions (with 
guidance kindly provided by Jack Rhyan, USDA/APHIS National Wildlife Research 
Center, Fort Collins, CO). The presence or absence of microgranulomas (early lesions), 
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characteristic tuberculous granulomas and mature lesions with calcified, necrotic 
centers were all noted in each target tissue. Any detection of acid fast bacilli was also 
noted. 
 Mycobacterial cultures were performed on the same target tissues that were 
collected in Whirl Pak® (Nasco, Fort Atkinson, Wisconsin, USA) bags and stored at -70 
oC until being sent to the USDA APHIS NVSL in Ames, Iowa. Mycobacterial cultures 
were performed as previously described (88). Briefly, tissues were trimmed, 
homogenized in a phenol red broth and decontaminated with 4% NaOH for 10 minutes.  
Once samples were neutralized with 6% HCl, they were centrifuged at 4,600 x g and the 
pellet was inoculated into both BACTEC MGIT media and 7H11 Middlebrooks with 
hemolyzed blood, calf serum, pyruvate and malachite green as additives. Media were 
incubated according to manufacturer’s recommendations, and signal positive tubes or 
bottles were examined for the presence of acid fast bacteria.  If the media signaled 
positive prior to 42 days and no acid fast organisms were detected, they were incubated 
at 37C for the full 42 days before being restained.  All suspicious colonies were 
identified as M. bovis by PCR (Dykema, 2016). 
 
2.3 Statistical Analysis 
 R: A language and environment for statistical computing (Vienna, Austria) was 
used for analyses online. Data across all four groups and all variables showed skewed 
distribution when plotted as histograms. Taking that into consideration, without 
normality, Spearman non-parametric correlation and linear regression were both used 
to analyze the relationship of lesion scores with histopathology, culture, and serum 
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antibody levels between all pigs. Kruskall-Wallis non-parametric tests were used to 
compare treatment groups by these individual variables (lesion score, histopathology, 
culture, antibody levels), to compare average antibody levels at each time point (1-5), 
and to test for confounding by gender bias.  
 
2.4 Results 
2.4.1 Necropsy: Gross pathology 
 On necropsy, the severity of gross pathology was assessed by macroscopic 
lesion scoring of target tissues listed in the methods sections and displayed on the 
necropsy worksheet (Appendix 1). Any exceptions to those listed in the rubric were also 
noted at the time of post mortem examination and during tissue preparation of histology 
slides. These exceptions included areas of tissue pathology that could not be grossly 
confirmed as a tuberculosis-related lesion or may have been in a tissue that was not 
considered a target organ. Superficial cervical lymph nodes with areas of characteristic 
granuloma formation were seen in 7 out of 8 pigs from the Michigan group. Suspect 
lymphoid hyperplasia of mesenteric, hepatic, ileocecal, parotid lymph node or tonsilar 
tissues were seen in 3 Michigan, 3 Spanish, 3 BCG, and 1 control group pig. Abscesses 
of the tonsils were seen in one Michigan pig. Central calcification or necrosis was noted 
in the mandibular or hepatic lymph nodes of 2 control, 2 BCG, and 1 Michigan pig, and 
was noted in the liver and spleen of 1 control and 1 Michigan pig.  
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	 Figure 4     Figure 5 
 Figure 4: macroscopic granulomatous tubercules at parenchymal surface of the lung lobe. 
 Figure 5: cross section of a mandibular lymph node with lesions measuring 8x10cm across. 
 
 
2.4.2 Necropsy: Lesion scoring 
 Total lesion scores from each pig were tallied and graphed as a group then 
compared to the other treatment groups – see Tables 1-4 and Figure 7. The mean 
treatment group scores from lowest to highest were: 6.1 (Spanish), 6.7 (Control), 8.1 
(BCG), and 15.25 (Michigan). The median scores from lowest to highest were: 5 
(Control and BCG), 6 (Spanish), and 11.5 (Michigan).  Total group scores from lowest to 
highest were: 43 (Spanish, n=7), 47 (Control, n=7), 57 (BCG, n=7), and 122 (Michigan, 
n=8). Every animal, regardless of group, had macroscopic lymph node lesions. The 
BCG vaccination group had the lowest total lymph node lesion scores, although this 
group had the animal with the most severe lung lesions. The Control and Spanish M. 
bovis vaccination groups had no lung lesions. The Spanish M. bovis vaccination group 
was the only group that had no lesions on major organs (liver, spleen, kidney). The 
Michigan M. bovis vaccination group had the animals with the most severe organ and 
lymph node lesions as well as the animal with the highest lesion scores overall (Pig ID: 
38 with a score of 37). Lesions scores ranged from 2 (BCG ID: 4, Spanish ID: 20) to 37. 
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Table 1: Gross lesion scores in the Control group with individual pig totals, system (lung/organ/lymph 
node) totals, and overall group total, mean, and median. 
GROUP	 Control	
PIG	ID	 37	 17	 2	 3	 19	 26	 30	 Total	
LUNGS	 0	 0	 0	 0	 0	 0	 0	 0	
ORGANS	 0	 0	 1	 2	 0	 1	 0	 4	
LYMPH	N	 10	 4	 12	 5	 4	 4	 4	 43	
TOTAL	 10	 4	 13	 7	 4	 5	 4	 47	
		 		 		 Control	group	total	=	47,	Mean	=	6.7,	Median	=	5	 		 		
	
Table 2: Gross lesion scores in the Michigan M bovis strain vaccine group with individual pig totals, 
system (lung/organ/lymph node) totals, and overall group total, mean, and median. 
GROUP	 Michigan	
PIG	ID	 9	 27	 38	 28	 8	 4	 22	 29	 Total	
LUNGS	 0	 4	 8	 0	 0	 0	 0	 4	 16	
ORGANS	 2	 2	 4	 1	 0	 3	 3	 3	 18	
LNN.	 10	 14	 25	 10	 8	 3	 6	 12	 85	
TOTAL	 12	 20	 37	 11	 8	 6	 9	 19	 122	
		 		 		 Michigan	group	total	=	122,	Mean	=	15.25,	Median	=	11.5	 		 		
	
Table 3: Gross lesion scores in the Spanish M bovis strain vaccine group with individual pig totals, 
system (lung/organ/lymph node) totals, and overall group total, mean, and median. 
GROUP	 Spanish	
PIG	ID	 39	 10	 18	 21	 1	 20	 7	 Total	
LUNGS	 0	 0	 0	 0	 0	 0	 0	 0	
ORGANS	 0	 0	 0	 0	 0	 0	 0	 0	
LYMPH	N	 6	 6	 5	 3	 7	 2	 14	 43	
TOTAL	 6	 6	 5	 3	 7	 2	 14	 43	
		 		 		 Spanish	group	total	=	43,	Mean	=	6.1,	Median	=	6	 		 		
	
Table 4: Gross lesion scores in the BCG M bovis strain vaccine group with individual pig totals, system 
(lung/organ/lymph node) totals, and overall group total, mean, and median. 
GROUP	 BCG	
PIG	ID	 6	 11	 5	 23	 25	 12	 24	 Total	
LUNGS	 0	 0	 0	 0	 15	 0	 0	 15	
ORGANS	 0	 0	 1	 0	 0	 1	 0	 2	
LYMPH	N	 4	 6	 4	 8	 12	 4	 2	 40	
TOTAL	 4	 6	 5	 8	 27	 5	 2	 57	




	 Figure 6: Gross lesion scores (totals from each individual animal)  
 compared across all 4 groups. The red X’s signify means and  







 Microscopic lesions were identified as present or not, and differentiation between  
immature and mature lesions with calcified/mineralized centers was made in each  
tissue. The presence of acid fast bacilli on special stained slides was noted in very few  
slides, and typically only 1 organism was identified on the entire slide (results not  
reported). Table 5 shows the results of histopathologic analysis on each pig. All pigs,  
regardless of treatment group, developed lymph node lesions, and only 2 (1 control and 
1 BCG pig) did not have calcified necrosis of these lesions. 7 out of 8 Michigan pigs and  
1 BCG pig were the only animals with major organ lesions on histopathology. Lung  
lesions were scattered among all treatment groups. The Michigan treatment group had  
animals with the most lung, major organ, and lymph node lesion locations. The average 
number of locations with lesions per group from smallest to largest were  
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Figure 7: Histopathologic lesions with characteristic tuberculosis granulomas using 
hematoxylin-eosin stain (A-D) and acid fast stain (E) on light microscopy at 10x (A, C, D) and 






Table 5: Number of tissues with bTB consistent granuloma lesions on histopathologic exam of H&E 
stained sections from target lungs, organs, and lymph nodes. Tallies from each pig with early or calcified 
lesions were totaled for each treatment group, and the group mean of pathologic tissues was calculated. 
Group	 Pig	ID	 Early	lesion	locations	 Calcified	locations	 Total	 Mean	
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			 22	 1	 1	 4	
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			 29	 1	 1	 2	
	 	
4	 8	
	Group	 Total	 6	 9	 15	
	












































































17	 2	 1	 8	 32	 4.6	
  
2.4.4 Culture Scores 
 On necropsy, tissues scored for lesions were also sampled for culture (Table 5, 
Figure 8). Every animal had mandibular lymph nodes that cultured positive for M. bovis. 
The next most common site for positive culture was the palatine tonsil (in 23 out of 29 
animals) followed by the tracheobronchial and bronchial lymph nodes (16 and 15 
animals, respectively). The Michigan M. bovis strain vaccination group had the highest 
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combined number of culture positive samples (61) and three of the four pigs with the 
highest number of culture positive sites. Supervicial cervical lymph nodes only cultured 
positive in the Michigan group, of which 7 out of 8 pigs cultured positive, consistent with 
gross lesion data. The group with the lowest number of combined culture positive 
samples was the control group (32) followed by BCG (35) and the Spanish M. bovis 
strain (42) vaccine groups. A score was assigned to each pig as the number of sampled 
tissues culturing positive for M. bovis. 
 
Table 6: the results of culture samples for each animal in all 4 groups.  B = M. bovis positive culture result 
in the specified tissue. 3 in the cranial lung row for Pig ID: 8 signifies that 3 of 4 lung tissues were culture 
positive. The miscellaneous row designates a positive, unidentified lymph node culture from Pig ID: 8, 9.  
Pig ID: 37    17  2 3 19 26 30 9 27 38 28 8 4 22 29 39 10 18 21 1 20 7 6 11 5 23 25 12 24 
Cranial lung   B    B  B B B 3   B B B      B   B B   
Cardiac lung B  B    B  B B     B B       B    B   
Diaph. lung   B    B  B B      B B B     B  B B B B  
Access. lung   B    B  B B     B B B             
Liver           B                    
Spleen          B                    
Kidney                              
Ileocecal Jxn                              
Mandib lnn. B B B B B B B B B B B B B B B B B B B B B B B B B B B B B 
Parotid lnn B    B B      B     B B  B B B   B  B  B 
Retroph lnn     B B   B B B B     B   B     B B   B 
Mediast lnn          B                 B   
TrachB lnn.  B B   B   B B B B B B B  B    B B    B B B  
Bronchial lnn B B B   B   B B B    B B B B  B  B    B B   
S Cerv lnn.        B B B B B  B B               
Mesent lnn.                 B     B   B     
Ileocecal lnn                      B        
Tonsil B B B B B B B B B B B   B B B B B B B B  B   B B  B 
Hepatic lnn B  B   B B   B B B   B B    B  B B       
Misc.        B    B                  
Total 6 4 9 2 4 7 7 4 10 14 8 10 2 4 9 8 10 5 2 6 4 7 6 1 5 7 9 3 4 
Group total 
Control = 32 
Average = 4.6 
Michigan = 61 
Average = 7.6 
Spanish = 42 
Average = 6 
BCG = 35 




Figure 8: Culture scores (number of M. bovis positive tissue  
cultures per animal) compared across all 4 groups. The blue X’s  
signify means and red bars signify medians for each group.  
 
2.4.5 Enzyme Linked Immunosorbant Assay – ELISA 
 The sensitivity of our ELISA test was 25 out of 29 (86.2%) that had a positive 
antibody level/E% results out of the pigs that were culture confirmed positive. ELISAs 
conducted on serum from time points 1, 2, and 3 revealed negative E% readings 
(<100), indicating a lack of anti-bPPD antibody production in any of the treatment 
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groups prior to (Time 1), four weeks-post (Time 2), and sixteen weeks-post (Time 3) 
vaccination. The first detectable antibodies were produced in all four groups at Time 4, 
four weeks post-challenge with the pathogenic field strain of M. bovis.  Antibodies levels 
persisted in animals until Time 5, fifteen weeks post-challenge. Antibodies were 
quantified by average E% and optical density at a ELISA 1:40 plate dilution from each 
animal sample run in duplicate. Figure 10 compares the average E% at time points 1-5 
between each group.  
 
Figure 9: Antibody levels against mycobacterial antigens from serum samples in each vaccination group 
were determined from bPPD ELISA. The average E% from each vaccination group at time points 1-5 
were compared. E% values below 1 are negative, and values above 1 are positive. 
 
 
2.4.6 Statistical analyses 
 Spearman non-parametric rank-based correlation tests revealed a moderate 
relationship between lesion scores and histopathology (0.609), cultures (0.575), and an 
insignificant relationship between lesions and antibody levels/E% (with outliers:0.204, 
without outliers/negatives: 0.259).  
 Kruskall Wallis rank sum tests demonstrated a statistically significant difference 









































(p=0.0122) and histopathology scores (p=0.0030). All groups were not significantly 
different from each other when comparing culture (x2 = 2.4278, p=0.49) and antibody 
levels (E%/OD, x2 = 0.3702, p=0.94). Boxplots of the data comparing groups with each 
variable (lesions, histopathology, culture, antibody levels) are displayed in Appendix 2. 
Confounding due to gender bias was not found when comparing female and male 
results for lesions (x2 = 0.0019, p = 0.4824) or antibody levels (x2 = 0.56, p=0.228). 
Boxplots comparing data between female and male pigs are displayed in Appendix 2. 
 Regression analysis scatterplots are displayed for visualization (Appendix 3) 
which indicated the same moderate relationship between lesions and histopathology (R2 
= 0.5426, p<0.05), lesions and culture (R2 = 0.4764, p<0.05), as well as no significant 
relationship between lesions and antibody levels, with or without outliers included (OD: 
R2 = 0.0089, p>0.05; E% without outliers: R2 = 0.0269, p>0.05). 
 
2.5 Discussion 
 This vaccine trial is the first investigation on inactivated M. bovis vaccination as a 
sustainable approach to bTB control in North American feral swine.  Our study is also 
the first to examine BCG vaccinated North American feral swine after experimental 
challenge with pathogenic M. bovis. Comparisons between lesion scores, microbial 
cultures, histopathology, and anti-bPPD antibody levels in vaccinated and non-
vaccinated animals after Mycobacterium bovis challenge were made. We planned to 
deem vaccination successful if the numbers of animals with lesions in the control group 
was at or exceeded 90% and the number of animals in the vaccine groups with lesions 
was at or below 30%. Instead, 100% of pigs in the trial developed lesions. It has been 
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shown that the number of lesions and number of tissue sites containing lesions 
compatible with bTB have a linear, positive correlation with severity of disease and level 
of shedding capacity in calves (90). We suspect swine develop a similar association 
between disease severity and transmission potential by pathogen shedding. Vaccine 
efficacy imparting protection against lesion development, measured by a statistically 
significant reduction in lesion scores and a reduction in the number of animals with 
lesions, would serve as a tool for control of bTB by lowering transmission risk. 
Immunologic research has shown us that cell-mediated response to M. bovis 
infection tends to occur earlier in disease progression, while humoral antibody 
responses are seen during further development of fulminant disease or exposure in 
cattle, swine, and other species (25, 28, 91). This may limit antibody detection in 
animals that are orally vaccinated with an inactivated dose of M. bovis, as previous 
vaccine trials have demonstrated that significant antibody levels were reached only after 
parenteral administration of inactivated vaccine or challenge with virulent M. bovis (13, 
73).  This is the same trend we saw in our results, as none of our orally vaccinated pigs 
had antibody production after vaccination, but did produce antibodies after pathogenic 
M. bovis challenge. Results of previous M. bovis vaccine and experimental infection 
trials revealed that tuberculosis lesion and culture scores were both negatively 
correlated with antibody levels against NADP-dependent alcohol dehydrogenase C 
(NADPAD) and MPB83 M. bovis antigens while positively correlated with antibody 
levels against purified bovine tuberculin protein derivative (bPPD) in wild boar – 
indicating a protective or pathologic association with humoral response depending on 
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the specific antibody produced (13, 73).  Our study showed no correlation, negative or 
positive, between lesions and antibody responses.  
We expected the vaccines produced with inactivated Michigan strain M. bovis or 
Spanish strain M. bovis, as well as modified-live BCG would impart some level of 
protection (at least a 60% reduction in lesions) in feral swine from disease caused by 
virulent M. bovis challenge with 1x106 CFU.  Unfortunately, pigs in the Spanish and 
Control groups developed similar, less severe disease than those in BCG and Michigan 
vaccination groups based on gross lesion scoring and histopathology. Pigs in the BCG 
and control groups also had the fewest tissues culturing positive, while pigs in the 
Michigan group developed the most severe tissue pathology in all lesion and culture 
assessments. We also anticipated that lesion scores and microbial cultures would be 
positively correlated to one another, and that was confirmed based on our statistical 
analyses. Knowing that antibody levels increase with the progression of clinical disease 
in swine species, we expected to see lesion severity positively correlated with antibody 
production, but this was not the trend seen in our data. This may be because lesion 
severity may indicate immune system ability to wall-off the organism in granulomatous 
structures, while antibody levels can indicate a systemic infection that has spread 
beyond isolated tissues or simply an exposure to the pathogen in the absence of 
fulminant infection. We hypothesized that the most significant reduction in clinical 
severity of bTB using an orally administered inactivated regional strain (i.e. Michigan) of 
M. bovis in our subjects, as it could impart the most specific immune defense against 
experimental infection with the same, genetically identical strain. Instead, we saw the 
most severe disease develop in the Michigan M. bovis strain vaccination group, and had 
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statistically significant gross lesion and histopathology scores that were much worse 
than the other groups. Without fully understanding the complex immunologic 
mechanism behind M. bovis infection and vaccination, especially in North American 
feral swine species, we can only speculate why the bovine strain of Michigan M. bovis 
used for vaccination was incapable of inducing an adequate immunologic defense 
against the virulence of the same strain in our swine subjects.  
The reason for failure of all three vaccines we tested is unknown, but we have 
considered a few theories. A study on wild boar in Spain revealed that co-infection with 
Porcine Circovirus 2 or pseudorabies disease virus, age, and Metastrongylus spp. lung 
nematode infestation was positively correlated with more severe bTB disease lesions 
(63). Our research subjects tested negative to pseudorabies and were on a deworming 
regimen, but we may consider concurrent parasitic infection or pathogenic immune 
system interference as contributors to M. bovis vaccination failure, although we do not 
consider this a highly likely cause. Undetected environmental mycobacterial exposure 
may have contributed to lack of protective immunity as has been demonstrated 
previously (92). Additionally, our pigs were approximately 6 months of age at the time of 
vaccination, and may have been too mature to develop an appropriate immunogenic 
response to the vaccines before experimental infection occurred. Successful M. bovis 
vaccination in previous studies was performed in pigs at 3-4 months of age (12, 13, 24, 
73), and other vaccine studies in people and animals have determined that age can 
interfere with protective response to vaccination (3, 69, 92).  
Other considerations we have made in regards to vaccination failure involve 
booster vaccination and route of administration. One study demonstrated that BCG 
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given twice (prime and booster) increased the protective capabilities of this vaccine in 
wild boar (24), while two vaccines of BCG have failed to protect from bTB development 
in African buffalo and were worse with two compared to one vaccine in calves (64, 69). 
The two vaccination trials using oral baits to deliver inactivated vaccine to wild boar 
were delivered in one dose (73) or with a booster dose 52 days after the initial vaccine 
(13), and did impart protection in piglets after challenge with virulent M. bovis 
innoculation. Our trial instead administered a booster of inactivated vaccine to the 
subjects 30 days after the first, no booster to the BCG vaccinates, and vaccines were 
delivered via syringe to the oropharynx rather than in bait form.  
Another difference in our trial from previous studies in Spanish wild boar was the 
dose of inactivated M. bovis vaccine given and of the pathogenic M. bovis strain 
challenge. Two doses of 1x107 CFU (13) or one dose of 6x106 CFU (73) inactivated M. 
bovis strain vaccine were delivered via oral baits to Spanish wild boar, while our trial 
administered two doses of 1x106 CFU inactivated M. bovis strains (Michigan or 
Spanish) to the oropharynx. Two doses of 1x106 CFU (24) and one dose of 1x105 CFU 
(12) BCG vaccine were administered in baits to Spanish boar piglets, while our trial 
administered one dose of 1x106 CFU BCG strain vaccine to the oropharynx.  Five mLs 
of 1x105 CFU (13, 24) and five mLs of 1x106 CFU (73) suspended pathogenic M. bovis 
was administered at challenge. Our study challenged with 1x106 CFU pathogenic 
Michigan field strain M. bovis. Although the CFU of our BCG vaccine was the same, the 
inactivated vaccine CFU was smaller than in the vaccine study by Ballesteros et. al. 
2009 (12). A low dose of BCG M. bovis vaccine has been shown to lack protective 
effects that are imparted by larger, verified doses of vaccine (93). The equivalent 
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pathogenic challenge dose we gave should have been equally likely to cause disease or 
be protected against after vaccination. Our use of a completely different virulent strain of 
M. bovis (Michigan vs. Spanish) that came from an entirely different species (bovine vs. 
porcine origin), may have contributed to a difference in pathogenicity and failure of the 
vaccine to protect against it compared to the European research.  
Different breeds, or even individuals, of the same species have the potential to 
mount different immunities after vaccination and to be more or less susceptible to 
infection with a pathogen. A study performed across South Central Spain sampled 
multiple populations of wild boar, and lack of genetic variation (homozygosity) was 
linked to increased likelihood of infection and disease progression in the Iberian wild 
boar population (94). If across one region of Spain, native wild boar populations show 
contrasting genetic influences on immunity, we speculate that there must be differences 
in genetic makeup between Spanish boar and feral swine of North America. Feral swine 
in North America are a non-native population of hybrids carrying multiple breeds of 
domesticated swine genetics. This genetic variability may explain a difference in 
immunity after M. bovis vaccination and the ability to develop infection with virulent M. 












The ultimate goal of our vaccine trial and studies like it was to demonstrate the 
protective benefits and reduced clinical severity of bTB after vaccinating with an 
inactivated M. bovis vaccine adapted for oral delivery to North American feral swine.  
The application of such preventative measures to decrease disease burden and 
environmental M. bovis shedding would theoretically reduce the shedding and therefore 
the transmission rate of disease. Determining whether shedding capacity is correlated 
with level of disease severity in vaccinated and unvaccinated animals would also be 
helpful for assessing the risk of M. bovis transmission from North American feral swine.   
Follow-up research will continue to investigate the efficacy of orally administered 
inactivated M. bovis vaccine in feral swine originating from Texas as well as swine 
originating from Molokai. These follow-up experiments will be needed to investigate 
vaccine efficacy and immune parameters in North American feral swine, and study 
focus should be on specifications for vaccine delivery (route, booster time-frame, dose, 
vaccine strain, etc.) that can lead to practical application in a field setting. Additionally, 
groups that are administered inactivated vaccine and controls will be intermingled to 
account for the possible bias caused by keeping each treatment in individual rooms. 
The BCG vaccinates will have to be kept separate so that potential shedding of the 
vaccine does not expose the other animals in the study.  
While we used bPPD ELISA technology to assess disease severity as it 
correlates with other quantifiable diagnostics (culture and lesion scores), a more 
species-specific assay differentiating vaccine-associated and infection-associated 
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antibodies (DIVA tests) in feral swine would be a more precise way to identify immune 
responses. Likewise, identifying the virulence and inoculation dose at which fulminant 
infection occurs from virulent strains, from Michigan or elsewhere, of M. bovis would be 
useful. Molecular markers such as IFN-γ, C3, IL-β, MUT, anti-MPB83 antibodies, etc. 
may be another way to qualitatively evaluate the innate and adaptive immune system 
defenses being stimulated by a particular vaccine in a particular strain of pig.  
 Finally, updated tuberculosis epidemiology, and animal ecology surveys are 
needed in areas of the US where feral swine populations are migrating into locations 
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Figure 10: Comparison of Control, Michigan, Spanish, BCG group lesion score data. 
Kruskall Wallis rank sum test: Michigan was statistically different (p < 0.05). 
 
Figure 11: Comparison of Control, Michigan, Spanish, BCG group histopathology data. 




Appendix 2 (continued) 
 
Figure 12: Comparison of Control, Michigan, Spanish, BCG group culture results. 
Kruskall Wallis rank sum tests: all groups were not statistically different (x2 = 2.4278, p=0.49). 
 
Figure 13: Comparison of Control, Michigan, Spanish, BCG group antibody levels. 
Kruskall Wallis rank sum tests: all groups were not statistically different (x2 = 0.3702, p=0.94). 
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Appendix 2 (continued)  
		
Figure 14: Comparison of female and male lesion score data. 
Kruskall Wallis rank sum test: groups were not statistically different (x2 = 0.0019, p = 0.4824). 
 
Figure 15: Comparison of female and male antibody levels (E%) 








Figure 16: Linear regression relationship between histopathology and lesion scores from all 





Figure 17: Linear regression relationship between culture and lesion scores from all pigs in the 





Appendix 3 (continued) 
 
Figure 18: Linear regression relationship between average optical density (OD) and lesion 
scores from all pigs in the study. Analysis of lesions versus average OD with outliers  






Figure 19: Linear regression relationship between E% and lesion scores from all pigs in the 
study. Analysis of lesions versus Antibody Levels/E% without outliers (R2 = 0.02686, p = 0.434). 
 
	
